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INTRODUCTION
The pharmacokinetic properties of exogenous and 
endogenous compounds can be influenced by re-
versible binding to human serum albumin (HSA), 
which is thought to be one of the primary determi-
nants of the pharmacokinetic properties of drugs 
(1-4). Therefore, when evaluating interactions 
among drugs, it is important to be aware of pos-
sible identities of their binding sites on the protein 
because any alteration in drug-binding to HSA, 
including binding of the antihypertensive drugs, 
could lead to a change in pharmacokinetic proper-
ties. Human serum albumin can be immobilized in 
spherical, macroporous microparticles of polyacryl-
amide of about 1 µm in diameter with retention 
of its native properties (5). Results of different ex-
periments suggest that human serum albumin has 
a limited number of binding sites (4,6,7). On the 
basis of the probe-displacement method, there are 
at least three relatively-high specific drug-binding 
sites on the HSA molecule. These sites, commonly 
called warfarin, benzodiazepine, and digoxin-bind-
ing sites, are also denoted as Site I, Site II, and Site 
III respectively (4,8,9). It has been shown that diaz-
epam, digitoxin, and warfarin independently bind 
to albumin and can conveniently be used as mark-
ers of three separate, discrete binding sites on albu-
min (5). Since numbers of protein-binding sites are 
limited, competition will exist between two drugs, 
and the drug with higher affinity will displace the 
other, causing increased free drug concentration 
leading to higher toxicity (10-12). 
Plasma protein-binding properties are related to 
plasma clearance, elimination half-life, appar-
ent volume of the distribvution, and area under 
the curve. The beta-blockers comprise a group of 
drugs that are mostly used in treating cardiovas-
cular disorders, such as hypertension, cardiac ar-
rhythmias, or ischemic heart diseases. As a class, 
the beta-blockers are quite diverse from a pharma-
cokinetic perspective as they display a high range 
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of values in plasma protein-binding, percentage of 
drug eliminated by metabolism, or unchanged in 
the urine and in hepatic excretion ratio. In clinical 
practice, the beta-adrenergic antagonists are an ex-
tremely important class of drugs due to their high 
extent of use. The non-selective beta-blockers, in-
cluding propranolol, oxprenolol, pindolol, nadolol, 
timolol, and labetalol each antagonize both ß1 and 
ß2-adrenergic receptors (ARs). The selective antago-
nists, including metoprolol, atenolol, esmelol, and 
acebutolol,  have  much  greater  binding-affinity 
for the ß1-AR. The selective beta-blockers are nor-
mally indicated for patients in whom ß2-receptor 
antagonism might associate with an increased risk 
of adverse effects. Such patients include those with 
asthma, or diabetes, or with peripheral vascular 
diseases, or Raynaud’s disease (13). Of all known 
beta-adrenolytics, propranolol has the highest li-
pohilicity and can cross the blood brain barrier 
(BBB) whereas atenolol is a highly hydrophilic 
drug (partition coefficient of 0.02) (14). Hydro-
philic beta-blockers, such as atenolol, are advan-
tageous in patients who suffer from central ner-
vous side-effects (sleep disturbances, psychosis, 
depression, and hallucination) during therapy 
with lipophilic drugs (13). 
Lipophilic drugs, such as propranolol, are exten-
sively metabolized by the liver while hydrophilic 
beta-blockers, including atenolol, are predomi-
nantly excreted through the kidney (Table 1) 
(15,16). In patients with normal renal function, 
the atenolol half-life was calculated to be about 
six hours following single 100-mg oral dose. This 
value increased markedly in patients with renal 
insufficiency, and the blood clearance of atenolol 
was found to have a significant correlation with 
the glomerular filtration rate (17). 
Approximately 91-96% of propranolol can be 
bound to serum albumin or other proteins, mainly 
to ß1-acid glycoprotein and lipoproteins (18). It sug-
gests that the lipids circulating in plasma may act 
as an additional depot for propanolol. Circulating 
free fatty acids could displace the hydrophilic drug 
from its protein-binding site (18,19). Contrary to 
propranolol, atenolol is mostly excreted through 
kidneys, and its elimination could not only be in-
fluenced by displacement of the drug from albu-
min, but also by alterations in renal blood flow in 
patients with hyperlipidaemia (18).
An understanding of the binding chemistry of beta-
blockers, i.e. atenolol, with protein may help clini-
cians to interpret and predict differences among 
patients in pharmacologic response to these drugs. 
Competitive displacement is more significant when 
two drugs are capable of binding to the same sites 
on the protein. Although information resource re-
garding the binding of drugs to HSA is extensive, 
the mechanism of drug-binding to HSA is still a 
subject of speculation and controversy (10,11,20). 
Again, arsenic has a tendency to bind strongly to 
protein. In our rural people who are at a higher risk 
of arsenic ingestion in their daily water-use, the 
blood arsenic concentration increases (10,11). Con-
sidering this, the purpose of our work was to in-
vestigate the effect of arsenic on the concentration 
of the common antihypertensive drug (atenolol, a 
beta-blocker). Human and bovine serum albumin 
exhibit similar binding chemistry due to the high 
percentage of sequence identities between the two 
proteins (21). Bovine serum albumin (BSA), in lieu 
of HSA, was used in this study because of its low 
cost and easy availability.
MATERIALS AND METHODS
Drugs and reagents used in the experiment
Atenolol (General Pharmaceutical Ltd., Bangladesh) 
warfarin, diazepam, disodium hydrogen phosphate 
(Na2HPO4), potassium dihydrogen phosphate 
(KH2PO4), cellulose nitrate membrane (Medicell 
International Ltd., Liverpool Road, London, UK; 
molecular wt 1,200 Daltons), bovine serum albu-
min (BSA) (fatty acid-free, fraction V, molecular wt 
66,500 from Sigma Chemical Ltd., USA), arsenic tri-
oxide (As2O3), and sodium arsenate.
Instruments used
The following instruments were used: pH Meter 
(HANNA Microprocessor pH Meter, Portugal), SP8-
400 UV/VIS Spectrophotometer (Thermospectron-
ic, England), Metabolic Shaking Incubator (Clifton 
Table 1. Pharmacokinetic properties of atenolol (15)
Substance Resorption 
%
Bioavailability 
%
T1/2
(h)
Active me-
tabolite
PPB
%
Vd 
l/kg
Total 
clearance
(mL/min)
Renal 
clearance
(mL/min
Atenolol 50 50 6-9 -- 3 0.7 100-180 100-170
min=Minute; PPB=Plasma protein-bindingAlam MA et al. Protein-binding interaction of atenolol with arsenic
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Shaking Bath, Nical electro Ltd., England), and Mi-
cro Syringe (well. Liang. Jin. Yang.q.I., China.) 
Method used
Equilibrium dialysis was employed in the study 
(22,23). 
Site-specific probes method
We have used different site-specific probes to en-
hance our understanding of the drug-BSA interac-
tion and thereby characterization of binding sites 
of the drugs used in the study on the BSA molecule 
(4,8,9,22,23).
Two site-specific probes were used. These are: (a) 
Warfarin sodium (Site I-specific probe) and (b) Di-
azepam (Site II-specific probe) that may be used for 
the identification of the binding sites of the drugs 
on BSA.
In the direct procedure, the ratio of BSA and probe 
(either warfarin or diazepam) was 1:1 (2×10-5 M: 
2×10-5 M), and different concentrations of drug 
were added. In the reverse procedure, the ratio of 
BSA and drug was 1:1 (2×10-5 M: 2×10-5 M), and dif-
ferent concentrations of probe (Site I-specific warfa-
rin sodium or Site II-specific diazepam) were added. 
After conducting equilibrium dialysis, the free con-
centration of probe will be determined in direct 
procedure and reverse procedure respectively. 
Preparation of standard curve 
Standard curve has been prepared using various 
concentrations and their corresponding concen-
tration at pH 6.4 and 7.4. Ultraviolet (UV) spec-
trophotometric scanning of the drugs—atenolol, 
diazepam, and warfarin—showed maximum ab-
sorbance of the UV light at 275 nm, 235 nm, and 
308 nm respectively. Atenolol showed linearity at a 
concentration range of 10-80 µM/mL with a confi-
dence level of 0.9984 and 0.9967 at pH 6.4 and 7.4 
with linear equation (Y=0.0107 X) and (Y=0.0146 
X) respectively. A similar standard curve was also 
prepared both for diazepam and warfarin, and the 
concentration of those drugs were calculated using 
corresponding linear equations.
Estimation of association constant of ateno-
lol at pH 6.4 and 27 0C temperature
Estimation of the association constant of atenolol 
was done at pH 6.4. Ten clean and dried test tubes 
were taken, and 3 mL of previously-prepared 2×10-
5 M BSA solution at pH 6.4 was taken in each of 
them. Aatenolol stock solution (1×10-2 M or 1×10-3 
M) was added in different volumes to nine of the 
10 test-tubes to have the following concentrations: 
0.5×10-5 M, 1×10-5 M, 2×10-5 M, 3×10-5 M, 4×10-5 M, 
5×10-5 M, 6×10-5 M, 7×10-5 M, 8×10-5 M, and 9×10-5 
M. The tenth test-tube containing only BSA solu-
tion at pH 6.4 was marked as ‘control’. After mix-
ing the solutions, these were allowed to stand 10 
minutes for maximum binding of atenolol to BSA; 
2 mL from each test-tube was pipetted out and 
poured onto previously-prepared semi-permeable 
membrane-tubes and, finally, both sides of the 
tubes were clipped properly so that there was no 
leakage. The membrane-tubes containing the drug-
protein mixture were immersed in ten 50-mL flasks 
containing 30 mL of phosphate buffer solution of 
pH 6.4. The mouths of the flasks were covered by 
foil-paper. These conical flasks were then placed in 
a metabolic shaker for dialysis for 10 hours at 27 
0C and 20 rpm. Buffer samples were collected from 
each flask after complete dialysis. Free concentra-
tions of atenolol were measured by a UV spectro-
photometer at a wavelength of 275 nm. 
Estimation of association constant of ateno-
lol at pH 7.4 and 27 0C temperature
To determine the association constant of atenolol 
at pH 7.4, a similar protocol as for estimation of 
the association constant of atenolol at pH 6.4 was 
followed using the buffer solution of pH 7.4. When 
dialysis was completed, buffer solutions were col-
lected from each conical flask, and the free concen-
tration of atenolol was measured by a UV spectro-
photometer at a wavelength of 275 nm.
Determination of binding site of atenolol us-
ing warfarin sodium as a Site I-specific probe
To determine the binding site of atenolol, using 
warfarin sodium as a Site I-specific probe, the suc-
cessive steps that were followed are described be-
low. 
From the previously-prepared 2×10-5 M BSA solu-
tion, 3 mL was taken in each of the eight cleaned 
and dried test-tubes; 1×10-3 M warfarin solution 
was added to seven of the eight test-tubes, and the 
final ratio of protein and warfarin was 1:1 (2×10-5 
M: 2×10-5 M) in each of these seven test-tubes. The 
eighth test-tube containing only BSA solution was 
marked as ‘blank’ or ‘control’. These mixtures were 
allowed to stand for 10 minutes for allowing bind-
ing of the warfarin to its particular binding site. 
Atenolol solutions (either 2×10-2 M or 2×10-3 M) was 
added with increasing concentrations into six of 
the seven test-tubes containing 1:1 mixture of pro-Alam MA et al. Protein-binding interaction of atenolol with arsenic
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tein-warfarin. The final ratios of protein: warfarin: 
atenolol were 1:1:0, 1:1:1, 1:1:2, 1:1:3, 1:1:4, 1:1:5, 
and 1:1:6. The remaining test-tube contained only 
protein-warfarin mixture (1:1). After pipetting, the 
solution was properly mixed and allowed to stand 
for 10 minutes to ensure maximum binding of 
atenolol to Site I and thereby displacing the probe 
from Site I on BSA. From each test-tube, 2 mL solu-
tion was taken into eight different semi-permeable 
membrane-tubes. The two ends of the membrane-
tubes were clipped to ensure that there was no 
leakage, and the rest of the experiment was done 
as described above using phosphate buffer solution 
of pH 7.4. 
Determination of binding site of atenolol us-
ing diazepam as a Site II-specific probe
To perform the experiment, the previously-de-
scribed procedure has been followed successively 
using diazepam solution. The final ratios of protein: 
diazepam: atenolol were 1:1:0, 1:1:1, 1:1:2, 1:1:3, 
1:1:4, 1:1:5, 1:1:6, and 1:1:9. Atenolol was not pres-
ent in the first test-tube which contained only pro-
tein-diazepam mixture (1:1). At the end of dialysis, 
samples were collected from each flask. The free 
concentrations of diazepam were measured using a 
UV spectrophotometer at a wavelength of 235 nm 
(BP). Reverse experiment was also being conducted 
followed by a similar protocol by adding diazepam 
in an increasing concentration and measuring the 
free atenolol concentration by spectrophotometer.
Effect of arsenic on atenolol-binding to BSA 
in presence of Site I-specific probe warfarin-
sodium 
From the previously-prepared 2×10-5 M BSA solu-
tion and 1×10-2 M warfarin solution, 2 mL and 12 
mL, respectively, were added to each of the seven 
cleaned and dried test-tubes. The final ratio between 
protein and warfarin was 1:1 (2×10-5 M: 2×10-5 M) 
in each of seven test-tubes so that Site I is suffi-
ciently blocked by warfarin-sodium. The seventh 
test-tube containing only BSA solution was marked 
as blank. After that, atenolol was added in six of the 
seven test-tubes, and protein-warfarin-atenolol ra-
tio was 1:1:1 (2×10-5 M:2×10-5 M:2×10-5 M ). Arsenic 
was added with an increasing concentration into 
five of the six test-tubes containing 1:2:1 mixture of 
protein-warfarin-atenolol to make the final ratio of 
protein-warfarin-atenolol arsenic 1:2:1:0, 1:2:1:1, 
1:2:1:2, 1:2:1:4, 1:2:1:6, 1:2:1:8, 1:2:1:10. Arsenic 
was not added to one test-tube. The solutions were 
then properly mixed and allowed to stand for 15 
minutes for the confirmation of maximum bind-
ing to BSA. After that, the solution was pipetted out 
and poured into seven semi-permeable membrane-
tubes. The two ends of the membrane-tubes were 
clipped to ensure that there was no leakage, and 
the rest of the experiment was done as described 
above using phosphate buffer solution of pH 7.4.
Effect of arsenic on atenolol-binding to BSA 
in absence of Site I-specific probe warfarin-
sodium 
To perform the experiment, the previously-de-
scribed procedure was followed successively in ab-
sence and presence of warfarin sodium. Arsenic was 
added with an increasing concentration to five of 
the six test-tubes containing 1:1 mixture of protein-
atenolol to make the final ratio of protein:atenolol: 
arsenic 1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:6, 1:1:8, 1:1:10. 
Arsenic was not added to the first test-tube which 
contained only protein-atenolol mixture (1:1). At 
the end of dialysis, samples were collected from 
each flask. The free concentrations of atenolol were 
measured by a UV spectrophotometer at a wave-
length of 275 nm (BP).
RESULTS
Both association constant (ka) and number of bind-
ing sites (n) of atenolol were determined using the 
Scatchard plot. To estimate the binding parameters 
of atenolol, equilibrium dialysis (ED) was used and 
the subsequent non-linear shape of the Scatchard 
plot describes both high- and low-affinity binding 
sites of drugs on protein molecule.
Determination of association constant and 
number of binding site
Atenolol was characterized by a high-affinity asso-
ciation constant (k1) to BSA and the value at pH 7.4 
was (4.6±0.151)x10-5 M (Table 2) while the low-af-
finity association constant (k2) for atenolol was 
found to be (3.03±0.086)x10-5 M. For this drug, the 
number of high-affinity and low-affinity binding 
sites was (0.61±0.199) x10-5 M and (1.33±0.114) 
x10-5  M  respectively  at  pH  7.4.  In  the  case  of 
atenolol bound to BSA, the high-affinity associa-
tion constant (k1) was found to increase when pH 
was changed from 7.4 to 6.4, and the value for k1 
and k2 was (5.06±0.202) x10-5 M and (4.23±0.159) 
x10-5 M respectively (Table 2). As a consequence 
for this drug, the number of high-affinity and low-
affinity binding sites was (0.81±0.04) x10-5 M and 
(2.03±0.201) x10-5 M respectively at pH 6.4. When 
the changes of physiological pH occur, BSA under-
goes conformational alteration, which is generally 
termed N-B transition. BSA remains almost entirely Alam MA et al. Protein-binding interaction of atenolol with arsenic
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in neutral form at pH 6 and in basic form at pH 
9. When the protein is in the B-conformation, 
fewer protons are bound to BSA than that in the 
N-conformation. Thus, the high-affinity and low-
affinity binding of atenolol is affected by change in 
pH. These differences in effect of pH may be due 
to the structural modification of protein molecule 
and, for this reason, at a given pH value, the bind-
ing site for atenolol is more suitable or properly ac-
commodated, while at other pH values, the binding 
sites become less convenient and less accommodat-
ing to the drugs in concern.
Determination of binding site 
Well-established probes, which are specific for par-
ticular sites on the albumin molecule, are used for 
the identification of the binding site of the drugs 
on the protein molecule. If a drug is able to displace 
a probe from its binding site, it is assumed that the 
drug also binds to that particular site. Thus, the 
binding site and specificity and relative strength 
of binding to albumin of atenolol have been de-
termined by this principle. Here, as Site I-specific 
probe, warfarin sodium and as Site II-specific probe, 
diazepam, were used. To characterize the binding 
site of atenolol, the free concentration of warfarin-
sodium (Site I-specific probe) bound to BSA was 
measured upon the addition of atenolol. It was 
found that the free concentration of warfarin-so-
dium increased from 14.966±0.351% (as % of ini-
tial) to 65.66±1.457% when the ratio of atenolol to 
BSA was increased to 6 (Fig. 1). In contrast, under 
the same experiment conditions when, in lieu of 
warfarin-sodium, diazepam was used as Site II-spe-
cific probe, the increment of the free concentration 
of diazepam by atenolol was from 11.166±0.152% 
(as % of initial) to 40.1±1.014% (Fig. 1). From these 
data, this is evident that, upon addition of atenolol, 
the increment of free concentration of warfarin-so-
dium is obviously greater than that of diazepam. 
Thus, it can be concluded that atenolol preferen-
tially binds to Site I. Again, as the displacement 
of diazepam is quite pronounced, it can be also 
suggested that atenolol, in addition to Site I, also 
binds to Site II on the BSA molecule but to a lower 
extent. In the reverse experiment, the free concen-
tration of atenolol was increased from 8.7±0.529% 
(as % of initial) to 71.133±1.059% when warfarin 
to BSA ratio was 6 (Fig. 2). On the other hand, the 
free concentration of atenolol was increased from 
13.933±0.702% (as % of initial) to 68.65±1.261% 
at the ratio of diazepam to BSA were also 6 (Fig. 
2). From these data, it is clear that the increment 
of atenolol due to displacement by warfarin (Site 
I probe) is higher than that of atenolol when dis-
placed by diazepam. Thus, the findings of the re-
verse experiment also were in agreement with the 
findings of the previous experiment.
Displacement of atenolol due to the effect of 
arsenic
During concurrent administration of atenolol and 
arsenic, site-to-site displacement takes place, and 
arsenic displaced atenolol from its binding sites 
(Fig. 3). In presence of probe, free concentration 
of atenolol was more prominent. This displace-
ment may be due to reduction of the binding site 
on bovine serum albumin. As observed from the 
model (Fig. 4), during concurrent administration, 
arsenic displaced atenolol from its high-affinity 
binding Site I. Thus, free concentration of atenolol 
increased from 4.286±0.629% and 5.953±0.605% 
to 82.153±1.924% and 85.486±1.158% in absence 
and in presence of Site I probe respectively.
DISCUSSION
In-vitro binding of water-soluble selective beta-ad-
renergic-blocker drug with bovine serum albumin 
was studied, and a lower association constant at 
pH 6.4 compared to pH 7.4 was found with a limited 
number  of  corresponding  binding  sites.  HSA  is  an 
abundant transport-protein found in plasma which 
binds a wide variety of drugs in two primary binding 
sites (I and II) that can have a significant impact 
on their pharmacokinetics (24). Site-specific displace-
ment interaction also provides information about 
the binding site. Atenolol substantially binds with 
Site I of BSA but also binds with Site II to a lesser ex-
Table 2. Parameters of atenolol bound to BSA at different pH values
pH
        Association constant           No. of binding sites
K1
(high affinity) 
× 10-5 M
K2
(low affinity) 
× 10-5 M
n1
(high affinity) 
× 10-5 M
n2
(low affinity) 
× 10-5 M
6.4 5.06±0.202 4.23±0.159 0.81±0.04 2.03±0.201
7.4 4.6±0.151 3.03±0.086 0.61±0.199 1.33±0.114
Values represent three consecutive experiments and expressed as mean±standard error of meanAlam MA et al. Protein-binding interaction of atenolol with arsenic
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tent. In a previous experiment, it was observed that 
the binding of arsenic to BSA occurred at Site II (9). 
The displacement interaction will be prominent for 
the binding, occurring at the same site. It should also 
be accountable for the binding to opposite site as 
these two binding sites exist in a transitional state.
Protein-binding of some beta-blockers was de-
termined in-vitro using equilibrium dialysis of 
labelled drug. Oxprenolol and propranolol were 
highly bound to serum, alprenolol, and pindolol, 
but timolol to a lesser degree, and atenolol, meto-
prolol and sotalol were negligibly bound (25). Bind-
ing studies with beta-adrenoceptor-blocking drugs 
in the presence of human plasma in combination 
with investigations of the sympatholytic activity in 
volunteers have shown that there is a correlation 
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Fig. 1. Free concentration of warfarin and diazepam bound to BSA upon the addition to atenolol
           at pH 7.4 and 27 0C
Values represent three consecutive experiments and expressed as mean±standard  deviation;
warfarin 2×10-5 M, diazepam 2×10-5 M, BSA 2×10-5 M, and atenolol 0-12×10-5 M were used
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between plasma levels and drug action (26). This 
is of major importance for the duration of action 
which depends on dose and plasma half-life. These 
observations may be of clinical significance as pa-
tients with coronary heart disease, who take their 
drug once a day in the morning, need protection 
for the rest of the day. It is known that the inci-
dence of silent ischaemic episodes, myocardial in-
farctions, and strokes increase in the early morning 
hours. Therefore, a preferential drug would guar-
antee a full therapeutic effect for 24 hours. ß-ad-
renoreceptor antagonists improve acute outcomes 
and long-term prognosis in ischemic heart disease 
(27) and reduce peri-operative events among high-
risk patients undergoing major non-cardiac and 
vascular surgery (28,29). The beta-adrenergic receptor 
is a glycoprotein (30). ß2-AR contributes to cardio-
vascular regulation by influencing several func-
tions, and results of previous studies suggest that a 
decreased function of the ß2-AR may be involved 
in essential hypertension. ß2-AR is polymorphic, 
and certain polymorphisms of these receptors are 
of functional importance (31). Stimulation of the 
ß1-AR in ß2-AR-KO myocytes produces the great-
est increase in contraction rate through a signal-
ling pathway that requires protein kinase A (PKA) 
activation. In contrast, stimulation of the ß2-
AR in ß1-AR-KO myocytes results in a biphasic 
effect on contraction rate with an initial increase in 
rate that does not require PKA, followed by a de-
crease in rate that involves coupling to a pertussis 
toxin-sensitive G protein (32). The beta-adrenergic 
receptor kinase (ß-ARK) specifically phosphorylates 
the agonist-occupied form of the beta-adrenergic 
and related G protein-coupled receptors (33). Ar-
senic-induced decreased expression of ß2-AR in 
cultured keratinocytes has also been reported (34). 
Recent studies of the effects of arsenic on cardiac 
electrophysiology have focused on arsenic trioxide 
(As2O3). The interest in studying arsenic trioxide 
is related to its use in the treatment of cancer, and 
some indications of heart problems associated with 
the treatment (35) reported that arsenic trioxide 
prolongs the duration of AP.
Ingested inorganic arsenic has been known to be re-
lated to the development of peripheral vascular dis-
ease and ischaemic heart disease among residents 
consuming water with high arsenic concentrations 
in Taiwan (36-39), Chile (40-42), and Mexico (43). 
A comparison of the prevalence of hypertension 
among subjects with and without arsenic exposure 
through drinking-water was done in Bangladesh. 
This study showed a dose-response relationship 
between inorganic arsenic exposure from drinking-
water and risk of hypertension (44). The effect of 
long-term exposure to inorganic arsenic on the de-
velopment of hypertension has rarely been studied, 
and the mechanism for inorganic arsenic to induce 
hypertension remains unclear (45). Long-term arse-
nic exposure has been documented to be associated 
with the development of peripheral neuropathy. 
Characteristic electromyographic changes include 
decreased nerve-conduction amplitude, with little 
changes in nerve-conduction velocity (46). Arsenic 
neuropathy has been classified as a distal axonopa-
thy with axonal degeneration, especially of large 
myelinated fibres of both sensory and motor neu-
rons (47). 
A target of arsenite in liver-cells may be the P450s, 
which are gene families of haemoproteins that cata-
lyze the oxidation of many endogenous and ex-
ogenous lipophilic chemicals (48). Earlier inves-
tigations revealed that severe exposure to arsenite 
reduces both basal and induced levels of some he-
patic P450s as measured spectrally or enzymatically 
(49,50) in rodents, and in primary cultures of rat 
hepatocytes, it has also been found to decrease in-
duction of CYP1A1/2, 2B1, and 3A23 (51). The effect 
of arsenite to decrease P450s may cause major im-
plications in human health by altering the metab-
olism and elimination of toxic chemicals and drugs 
that are substrates for such P450s. CYP3As are the 
most abundant P450 proteins found in the human 
liver, accounting for between 30% and 60% of the 
total cytochrome P450 content, with CYP3A4 being 
the major hepatic CYP3A present (52). In humans, 
CYP3A proteins are involved in the metabolism 
of 45% to 60% of all currently-used drugs (53,54). 
Therefore, variability in CYP3A4 enzyme system 
expression would be expected to have a profound 
effect on the efficacy and safety of drugs that have 
a narrow therapeutic index and are metabolized by 
CYP3As.
It was previously reported that 5 µM of arsenite 
not only decreases phenobarbital (PB)-induced 
CYP3A23 protein, with a little to no decrease in 
CYP3A23 mRNA, in primary cultures of rat hepato-
cytes (51) but also decreases CYP1A1 and CYP1A2 
expression in primary human hepatocytes (55), 
benzo[a]pyrene-induced CYP1A1 and CYP1B1 ex-
pression in T-47D human breast-cancer cells (56), 
and  benzo[k]-fluoranthene-mediated  induction  of 
CYP1A1 mRNA in HepG2 cells (57). Although the 
mechanisms underlying arsenite-mediated decrease 
in P450s have yet to be identified, several hypotheses 
have been generated, including transcriptional and 
post-translational events (56,58).
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insufficiency from cortical necrosis (59), and signs 
of arsenic-induced renal injury include haematu-
ria, leukocyturia, and glycosuria (60). The arsenic-
related hypertension observed in that study is the 
result of possible neurological, and renal defects 
induced by arsenic need further exploration. Treat-
ment for hypertension with beta-blockers in the 
arsenic-affected area where people are bound to 
drink  arsenic-containing  well-water  daily  should 
require additional precautions. Atenolol does not 
undergo hepatic metabolism and has rarely been 
associated with liver injury. Arsenic may cause re-
nal  insufficiency  which  could  lead  to  accumula-
tion of more atenolol in plasma because excretion 
of atenolol is totally dependent on renal function 
and increases its plasma half-life. Moreover, as 
shown in the present study, arsenic displaces the 
in-vitro atenolol binding to BSA and increases the 
free concentration of drug which may be available 
for further action upon the beta-receptor. Further 
research is needed to elicit the exact mechanism of 
drug interaction with arsenic and its binding with 
bovine serum albumin.
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